within Pharmacolibrary.Drugs.R_RespiratorySystem.R03A_AdrenergicsInhalants.R03AK08_FormoterolAndBeclometasone;

model FormoterolAndBeclometasone
  extends Pharmacolibrary.Drugs.ATC.R.R03AK08;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>R03AK08</td></tr><td>route:</td><td>inhalation</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Formoterol and beclometasone is a fixed-dose combination medicine consisting of formoterol, a long-acting beta-2 adrenergic agonist (LABA), and beclometasone dipropionate, an inhaled corticosteroid (ICS). This combination is primarily used for the treatment and management of asthma and chronic obstructive pulmonary disease (COPD). Both agents work synergistically to improve lung function and control symptoms. It is approved for therapeutic use in many regions and recommended in guidelines.</p><h4>Pharmacokinetics</h4><p>Estimated typical adult pharmacokinetic parameters for formoterol and beclometasone administered via inhalation, based on known data from individual monocomponents and similar combination products in healthy adults.</p><h4>References</h4><ol><li><p>Kuna, P, et al., &amp; Ciurlia, G (2022). Pharmacokinetics of extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide in adolescent and adult patients with asthma. <i>Pharmacology research &amp; perspectives</i> 10(4) e980–None. DOI:<a href=&quot;https://doi.org/10.1002/prp2.980&quot;>10.1002/prp2.980</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35733414/&quot;>https://pubmed.ncbi.nlm.nih.gov/35733414</a></p></li><li><p>Rony, F, et al., &amp; Klein, J (2024). Evaluating the pharmacokinetics of beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide delivered via pressurised metered-dose inhaler using a low global warming potential propellant. <i>Pulmonary pharmacology &amp; therapeutics</i> 85 102299–None. DOI:<a href=&quot;https://doi.org/10.1016/j.pupt.2024.102299&quot;>10.1016/j.pupt.2024.102299</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38663512/&quot;>https://pubmed.ncbi.nlm.nih.gov/38663512</a></p></li><li><p>Kuna, P, et al., &amp; Stelmach, I (2015). Pharmacokinetics and pharmacodynamics of an extrafine fixed pMDI combination of beclometasone dipropionate/formoterol fumarate in adolescent asthma. <i>British journal of clinical pharmacology</i> 80(3) 569–580. DOI:<a href=&quot;https://doi.org/10.1111/bcp.12640&quot;>10.1111/bcp.12640</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25808292/&quot;>https://pubmed.ncbi.nlm.nih.gov/25808292</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end FormoterolAndBeclometasone;
